Litcius/Paper detail

Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of <i>Enterobacterales</i> Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases

Cassandra L. Chatwin, Jodie C. Hamrick, Robert E. Lee Trout, Cullen L. Myers, Susan M. Cusick, Jason Weiss, Mark Pulse, L Xerri, Christopher J. Burns, Greg Moeck, Denis M. Daigle, Kaitlyn John, Tsuyoshi Uehara, Daniel C. Pevear

2021Antimicrobial Agents and Chemotherapy35 citationsDOIOpen Access PDF

Abstract

There is an urgent need for oral agents to combat resistant Gram-negative pathogens. Here, we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI), and its orally bioavailable etzadroxil prodrug, VNRX-7145.

Topics & Concepts

CephalosporinChemistryKlebsiella pneumoniaeCarbapenemMeropenemEscherichia coliPharmacologyMicrobiologyMedicineAntibioticsAntibiotic resistanceBiochemistryBiologyGeneAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPneumocystis jirovecii pneumonia detection and treatment